Zevra Therapeutics (ZVRA) to Announce Earnings on Wednesday

Zevra Therapeutics (NASDAQ:ZVRA) is projected to issue its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Zevra Therapeutics to post earnings of $0.08 per share and revenue of $33.8830 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.18 EPS for the quarter, topping the consensus estimate of $0.06 by $0.12. The company had revenue of $36.22 million during the quarter, compared to analyst estimates of $31.96 million. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 51.49%. On average, analysts expect Zevra Therapeutics to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Zevra Therapeutics Price Performance

Shares of Zevra Therapeutics stock traded up $0.18 during trading on Monday, hitting $9.70. The stock had a trading volume of 101,129 shares, compared to its average volume of 1,354,323. Zevra Therapeutics has a 12 month low of $7.16 and a 12 month high of $15.03. The firm’s fifty day simple moving average is $12.31 and its 200-day simple moving average is $10.52. The stock has a market cap of $573.12 million, a PE ratio of 4.87 and a beta of 0.85.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of ZVRA. Russell Investments Group Ltd. lifted its holdings in shares of Zevra Therapeutics by 235.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock worth $61,000 after acquiring an additional 4,475 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in Zevra Therapeutics by 617.5% during the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock worth $88,000 after purchasing an additional 8,552 shares in the last quarter. Creative Planning purchased a new position in shares of Zevra Therapeutics during the second quarter worth $92,000. Qube Research & Technologies Ltd acquired a new stake in shares of Zevra Therapeutics in the second quarter valued at $99,000. Finally, Quarry LP purchased a new position in Zevra Therapeutics during the 3rd quarter valued at about $103,000. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Wall Street Analysts Forecast Growth

ZVRA has been the topic of a number of analyst reports. BTIG Research cut their target price on Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating on the stock in a research note on Monday, July 27th. HC Wainwright reiterated a “buy” rating and set a $26.00 target price on shares of Zevra Therapeutics in a research report on Tuesday, June 23rd. Guggenheim cut their price target on shares of Zevra Therapeutics from $29.00 to $24.00 and set a “buy” rating on the stock in a report on Monday, July 27th. Citigroup reiterated an “outperform” rating on shares of Zevra Therapeutics in a report on Tuesday, June 9th. Finally, Maxim Group raised their target price on shares of Zevra Therapeutics from $25.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, June 10th. Nine equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $26.86.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.